10-K: Horizon Space Acquisition II Corp. Files 2025 Annual Report

Horizon Space Acquisition II Corp. has filed its 2025 Form 10-K, detailing its ongoing efforts to complete a business combination and its financial status.

Summary

• Horizon Space Acquisition II Corp. (HSPT) is a blank check company incorporated in the Cayman Islands on March 21, 2023, with the purpose of completing a business combination.
• The company consummated its initial public offering (IPO) on November 18, 2024, raising $60 million by selling 6 million units.
• An over-allotment option resulted in the sale of an additional 900,000 units, raising $9 million.
• The company entered into a business combination agreement with SL Bio Ltd. on May 9, 2025.
• Shareholders approved the business combination and amendments to the articles of association on February 12 and 13, 2026, respectively.
• The company has extended its deadline to complete a business combination multiple times, with the current target date being April 18, 2026, subject to further extensions up to February 18, 2027.
• As of December 31, 2025, the company had $7,917 in cash and a working capital deficit of $1,319,649.
• The company reported net income of $1,809,006 for the year ended December 31, 2025, primarily from interest income on its trust account.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern due to its lack of operations and reliance on future financing and business combination completion.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a neutral to slightly negative sentiment due to the ongoing going concern issues and the significant risks associated with completing a business combination, despite progress on the SL Bio deal.

Positives

• The company successfully consummated its IPO and over-allotment option, raising a total of $69 million.
• A business combination agreement has been executed with SL Bio Ltd., and shareholder approval has been obtained.
• The company has secured extensions to its business combination deadline, providing more time to finalize the transaction.
• Interest income from the trust account provided a net income of $1,809,006 for the year ended December 31, 2025.

Negatives

• The company has no operating revenue and has incurred losses since inception.
• As of December 31, 2025, the company had a working capital deficit of $1,319,649.
• The company's auditor has identified substantial doubt about its ability to continue as a going concern.
• Significant redemptions occurred in connection with shareholder meetings, totaling 3,219,311 shares redeemed in February 2026.

Risks

• The company may not be able to complete its initial business combination within the extended timeframe, leading to liquidation.
• The company's ability to continue as a going concern is subject to substantial doubt.
• Potential legal and operational risks associated with acquiring a company that does business in China, including regulatory uncertainties and enforcement challenges.
• The company may face difficulties in obtaining necessary approvals from PRC governmental authorities for a business combination with a China-based target.
• The company's ability to pay dividends to shareholders may be restricted by PRC foreign exchange control regulations if it acquires a China-based business.
• Enforcement of civil liabilities may be difficult if key officers and directors reside outside the United States.
• U.S. foreign investment regulations, including CFIUS review, could impact the ability to complete a business combination with a U.S. target.
• The company's rights may expire worthless if a business combination is not completed within the required period.

Future Outlook

The company's primary focus is on completing its initial business combination with SL Bio Ltd. The company has extended its deadline multiple times and is working towards consummating the transaction by April 18, 2026, with potential further extensions. Post-combination, the company anticipates listing on the Nasdaq Stock Market.

Management Comments

• "Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region. Because of our significant ties to China, we may pursue opportunities in China (including Hong Kong and Macau)."
• "We intend to utilize cash derived from the proceeds of our initial public offering (the IPO), our securities, debt or a combination of cash, securities and debt, in effecting a business combination."
• "We presently have no revenue and have had losses since inception from incurring formation and operating costs. We have relied upon the sale of our securities and loans from the Sponsor and other parties to fund our operations."
• "Our management has broad discretion with respect to the specific application of the proceeds of the IPO and the Private Placement that are held out of the Trust Account, although substantially all the net proceeds are intended to be applied generally towards consummating a business combination and working capital."

Industry Context

StockSavvy.ai notes that Horizon Space Acquisition II Corp. is a Special Purpose Acquisition Company (SPAC), a common vehicle for private companies to go public. The company's focus on potential opportunities in China, coupled with the complexities of PRC regulations and U.S. listing requirements, presents a significant risk factor common to many China-focused SPACs.

Comparison to Industry Standards

• As a SPAC, direct comparison to operating companies is not applicable. However, the IPO structure and trust account management align with industry standards for SPACs.
• The extension of the business combination deadline is a common practice for SPACs facing challenges in identifying and closing a suitable target, though the multiple extensions and associated costs are notable.
• The PIPE financing of $7.8 million is a standard component of SPAC transactions to provide post-merger capital, with terms similar to other recent SPAC deals.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material litigation or other legal proceedings.
• The company is not aware of any legal proceeding, investigation, or claim that has a more than remote possibility of having a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• The Sponsor purchased 200,000 Private Units at $10.00 per unit for $2,000,000.
• The Sponsor purchased an additional 13,500 Private Units at $10.00 per unit for $135,000.
• The company issued unsecured promissory notes totaling $990,000 to its Sponsor and designees for working capital and extension fees.
• The company has an amount due to related party of $354,484 as of December 31, 2025, representing advancements for formation, IPO expenses, and ongoing operations.
• An affiliate of the Sponsor was to be paid $10,000 per month for administrative support services, but this fee was waived.
• Founder shares were issued to the Sponsor and transferred to directors and officers at a nominal price.

Stakeholder Impact

• Shareholders: Public shareholders face the risk of their shares being redeemed if the business combination is not completed, and their rights may expire worthless. They are awaiting the completion of the business combination for potential value realization.
• Sponsor: The Sponsor has invested significant capital and has agreed to waive certain redemption rights, indicating a strong interest in the success of the business combination.
• Creditors: Proceeds in the trust account could be subject to claims from creditors, potentially having priority over shareholder claims.
• Management and Directors: Management and directors may have conflicts of interest due to their affiliations with other entities and potential compensation arrangements post-business combination.

Next Steps

• Complete the business combination with SL Bio Ltd.
• Obtain necessary regulatory approvals for the business combination.
• Manage ongoing operational costs and liquidity.
• Potentially pursue further financing if required post-business combination.

Key Dates

Recommendation

The company is in the process of completing a business combination, and its future performance is highly dependent on the success of this transaction. While progress has been made with SL Bio Ltd., significant risks remain, including the going concern issue and potential regulatory hurdles. Therefore, a 'hold' recommendation is appropriate pending further clarity on the business combination's completion and the target company's prospects.

Keywords

SPAC, Horizon Space Acquisition II Corp., Form 10-K, Business Combination, SL Bio Ltd., IPO, Trust Account, Cayman Islands, SEC Filing, Financial Report